Le Moci, the leading media outlet serving international trade professionals in France, awarded Hemerion the nationale LeadExport Trophy in the Innovation category in recognition of its international activities. This award recognises Hemerion’s efforts to accelerate the development of innovative cancer therapies on the global stage.
This distinction recognizes the international expansion strategy pursued by Hemerion, which is reflected in particular in the clinical development of its technology in the North American market, a key step in making the Pentalafen® / Heliance® solution accessible to patients worldwide.
Since its establishment in 2020, Hemerion has maintained an active international presence, with ongoing projects in Europe and the United States. These projects include:
- A Phase I/II clinical trial organized in partnership with the University of Pittsburgh Medical Center. Hemerion’s clinical development in the United States had already been recognized with the Galien MedStartup Award at the end of 2021 in New York.
- Our team has participated in dozens of international events, including BIO, the world’s leading pharmaceuticals and biotech convention, and CNS, the world’s leading international neurosurgery congress.
- We have also established a highly international Scientific Advisory Board.
- Hemerion regularly participates in French delegations for international development programs, such as French Tech and Business France.
- An ambitious research program developed with the University of Liège in Belgium.
